http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0712627-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ca2e4410855da087e11bf3eea8933fa |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-35 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D335-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-472 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-445 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D217-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-382 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D311-34 |
| filingDate | 1995-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_386de9f46839b5e03ec74b595316db1d |
| publicationDate | 1996-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0712627-A2 |
| titleOfInvention | Methods for lowering serum cholesterol |
| abstract | The present invention provides methods for lowering serum cholesterol comprising administering to a mammal in need of treatment a serum cholesterol lowering amount of a compound of formula I or formula IIn n wherein n R¹ is -H or is a bivalent moiety which distances L from the B-ring by 6-8 intervening atoms; n R is -H or selected from the group consisting of hydrogen, a straight or branched, saturated or unsaturated chain having 1-5 carbon atoms, a substituted or unsubstituted cycloalkyl group having 5-7 carbon atoms, a bivalent moiety which joins R³ and L to form a 5- to 7-membered heterocyclic ring, and halo-substituted derivatives of the foregoing; n R³ is absent or selected from the group consisting of hydrogen, a straight or branched, saturated or unsaturated chain having 1-5 carbon atoms, a substituted or unsubstituted bivalent moiety which joins R and L to form a 5- to 7-membered heterocyclic ring, and halo-substituted derivatives of the foregoing; n R⁴ is hydrogen or lower alkyl; n R⁵ and R⁶ each are independently hydrogen, hydroxy, or a moiety which is converted to hydroxy in vivo ; n L is -CON< or -N<; and n the dotted line in the B-ring is an optional bond; or a pharmaceutically acceptable salt thereof; andn n wherein n Q is a moiety having the formulan n or n n -R¹-B-R⁷-L-G; n n n R¹ is absent or is a bivalent moiety which distances L from the B-ring by 6-8 intervening atoms; n R is absent or selected from the group consisting of hydrogen, a straight or branched, saturated or unsaturated chain having 1-5 carbon atoms, a substituted or unsubstituted cycloalkyl group having 5-7 carbon atoms, a bivalent moiety which joins R³ and L to form a 5- to 7-membered heterocyclic ring, and halo-substituted derivatives of the foregoing; n R³ is absent or selected from the group consisting of hydrogen, a straight or branched, saturated or unsaturated chain having 1-5 carbon atoms, a substituted or unsubstituted bivalent moiety which joins R and L to form a 5- to 7-membered heterocyclic ring, and halo-substituted derivatives of the foregoing; n L is -CON< or -N<; n B is -O-, -S-, -CH₂-phenyl-O-, -phenyl-O-, or -benzyl-O-; n R⁷ is absent or selected from the group consisting of straight- or branched-chain alkylene, straight- or branched-chain alkenylene, phenylene, and fluoro-substituted analogs of the foregoing; n G is a moiety which together with L forms a substituted or unsubstituted heterocyclic ring having at least one nitrogen atom or is selected from the group consisting of hydrogen, lower alkyl, lower alkenyl, lower alkynyl, (C₃-C₇)cycloalkyl, halo(lower)alkyl, cyano(lower)alkyl, carboxy(lower)alkyl, (lower)alkoxycarbonyl(lower)alkyl, (C₆-C₁₀)aryl, (C₇-C₁₁)aryl akyl, di(lower)alkylamino(lower)alkyl, and fluoro-substituted analogs of the foregoing; n R⁴ is hydrogen or lower alkyl; n R⁵ and R⁶ each are independently hydrogen, hydroxy, or a moiety which is converted to hydroxy in vivo ; n Z is -O-, -S-, -CH₂-, -NH-; or -N(CH₃)-; and n the dotted line in the B-ring is an optional bond; or a pharmaceutically acceptable salt thereof. |
| priorityDate | 1994-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 241.